Predictive Biosciences,a Lexington,Mass.-based developer of intervention diagnostic assays for cancer management,has raised $21.75 million in Series B funding.New Enterprise Associates led the round,and was joined by Kaiser Permanente Ventures and return backers Flybridge Capital Partners and Highla [...]